HP Ingredients has announced five new published human clinical trials for its LJ100 Tongkat Ali (Eurycoma longifolia) ingredient.
Study 1 tested the effects of testosterone levels and quality of life in aging men. The randomized, double-blind, placebo-controlled, multi-center study found split 105 male subjects aged 50-70 years with low testosterone into three groups, and gave them 100mg of LJ100, 200mg of LJ100, or a placebo daily for 12 weeks. The findings:
- There was a significant increase in the total testosterone levels at week 12 in the 100mg group and starting at week 4 for the 200mg group compared to the placebo group.
- No significant between-group differences in free testosterone levels were observed; however, there was a significant within-group increase starting at week 4 in the 100 mg group, and starting at week 2 in the 200 mg group.
- The AMS and FSS showed significant reduction in total scores at all time-points within- and between-group in both LJ100 groups.
- DHEA levels significantly increased within-group in both LJ100 groups from week 2 onwards.
- Cortisol levels significantly decreased in the 200 mg group, while muscle strength significantly increased in both LJ100 groups at week 12.
- Conclusion: Supplementation of 200mg of LJ100 increases serum total testosterone, reduces fatigue, and improves the quality of life in ageing men within only 2 weeks.
Study 2 tested LJ100 on sexual health in men with androgen deficiency. The 6-month, double-blind, randomized, placebo-controlled trial split 45 men into four groups: control + placebo; control + LJ100; concurrent training + placebo; concurrent training + LJ100. The findings:
- Erectile function improved in the LJ100 groups.
- Concurrent training + LJ100 group showed the most significant results in improvement in International Index of Erectile Function (IIEF-5), Aging Male Scale (AMS) and total testosterone.
- Conclusion: 200mg LJ100 plus concurrent training improved erectile function and increased total testosterone levels in aging men with androgen deficiency.
Study 3 tested LJ100 for strength and cardiorespiratory fitness in men with androgen deficiency. The 6-month, randomized, double-blind, placebo-controlled clinical trial was performed on 45 men, who were randomized into four groups—control, LJ100, concurrent training, and concurrent training + LJ100. The findings:
- Isokinetic peak torque of the knee extensors increased in the CT (14%) and CT + LJ100 (17%) groups, the isokinetic peak torque of knee flexion increased in the CT + LJ100 group only.
- Testosterone levels were correlated with isokinetic peak torque of knee extension and flexion.
- Subjects of the CT (27.3%) and CT + LJ100 (36.1%) groups decreased the symptomatology of androgen deficiency.
- Conclusion: This study demonstrated the benefits of CT and LJ100 consumption as a non-pharmacological treatment for androgen deficiency.
Study 4 tested the effect of LJ100 on reproductive hormones in young men. The double-blind, placebo-controlled, matched-paired study included 32 men, who received 600mg/day LJ100 or placebo for two weeks. The results:
- LJ100 supplementation significantly increased Total Testosterone (+15.21% vs -2.78%), Free Testosterone (+34.12% vs +4%), and estradiol levels (+31.1% vs 20.2%) compared to the placebo.
- There was no change in luteinizing hormone, follicle-stimulating hormone and sexual hormone-binding globulin, suggesting a lesser role played by Eurycoma longifolia in activating the hypothalamic-pituitary-gonadal axis in the young adults.
- The raised testosterone levels may be due to a greater rate of hormone production via the hypothalamic-pituitary-adrenal axis.
- The supplementation of Eurycoma longifolia for two weeks demonstrates steroidogenic effects on young men were dose-related as the earlier study with 200mg did not show significant changes.
- Conclusion: The raised testosterone following LJ100 supplementations could benefit muscle and strength gain in young adults.
Study 5, from 2020, tested LJ100 for modulating menopause symptoms for women. The 24-week, randomized, double-blind, placebo-controlled study enrolled 119 healthy women aged 41-55 experiencing peri-menopausal or menopausal symptoms, and supplemented with 400mg L. pumila + 100mg LJ100, or placebo. The results:
- At week 12, significant improvements in hot flash symptoms were observed in the active group compared to placebo.
- Significant improvements in MRS and MENQOL scores at weeks 12 and 24 were observed in both groups, respectively.
- Luteinizing hormone and follicle-stimulating hormone levels were significantly reduced at weeks 12 and 24 in the Nu-femme group, with no significant changes in placebo group.
- Serum LDL-C and triglycerides were significantly reduced at week 12 in Nu-femme group; but no changes in placebo group.
- Conclusion: 400 mg L. pumila + 100 mg LJ100 may support reduction in hot flashes and improvements in hormone and lipid profile in healthy peri-menopausal and menopausal women.